Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo tested for tough cancers

NCT ID NCT06544655

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colon, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 213 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN). * Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1). * Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Exclusion Criteria: * History of or with active interstitial lung disease or pulmonary fibrosis. * Active, known, or suspected autoimmune disease. * Serious uncontrolled medical disorders. * New onset, non-catheter-associated venous thromboembolism within the past 6 months. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma pancreatic ductal adenocarcinoma Spinocerebellar Degenerations Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors

Contacts and locations

Locations

  • Local Institution - 0003

    Tucson, Arizona, 85719, United States

  • Local Institution - 0004

    Sioux Falls, South Dakota, 57104, United States

  • Local Institution - 0007

    Los Angeles, California, 90033, United States

  • Local Institution - 0011

    Grand Rapids, Michigan, 49546, United States

  • Local Institution - 0013

    San Antonio, Texas, 78229, United States

  • Local Institution - 0016

    Montreal, Quebec, H2X 0A9, Canada

  • Local Institution - 0017

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0019

    Elizabeth Vale, South Australia, 5112, Australia

  • Local Institution - 0021

    Darlinghurst, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.